Opportunity Information: Apply for PAR 20 083
Enhancing Regulatory Science for Advancing Pharmaceutical Quality and Manufacturing (U01) is an FDA cooperative agreement funding opportunity (PAR-20-083) designed to speed the practical use of advanced and emerging pharmaceutical manufacturing technologies while strengthening the science FDA and industry rely on to evaluate drug quality. The central motivation is straightforward: FDA regulates drug manufacturing to keep the US supply reliable and high-quality, and newer manufacturing approaches have the potential to reduce disruptions, prevent product failures, help address drug shortages, and ultimately lower costs. FDA is explicitly interested in technologies that are far enough along to be realistically implemented in industry, not purely early-stage concepts, because the intent is to generate knowledge and tools that can be used soon for real manufacturing and regulatory decisions.
A major theme of the announcement is that drug products are becoming more complex, which raises the bar for both manufacturing control and regulatory assessment. Complexity can come from the active ingredient itself (including difficult-to-characterize substances), the formulation (for example, enabling delivery of poorly soluble drugs), the dosage form, or specialized approaches tied to personalized or precision medicine. As complexity grows, FDA's Office of Pharmaceutical Quality is looking to refine and standardize best practices for risk-based quality assessment. At the same time, FDA acknowledges a practical problem: when a manufacturing technology is genuinely new to the sector, there is often limited shared experience and a thin evidence base for how to validate it, control it, and evaluate it consistently. This program is meant to close those gaps by funding work that produces usable, transferable regulatory science.
The opportunity has two closely linked objectives. First, it supports research that facilitates the implementation and assessment of emerging manufacturing technologies in the pharmaceutical sector. Second, it funds work that expands the knowledge base around complex drug products, particularly formulation development, analytical evaluation, and manufacturing control, so that FDA and industry can advance risk-based quality assessment for both new (innovator) and generic drug products. The emphasis on risk-based assessment matters because it aligns with modern quality paradigms: understanding what could go wrong, how likely it is, how severe the impact could be, and what controls and tests meaningfully reduce risk, rather than applying one-size-fits-all requirements.
FDA lays out the kinds of outcomes it expects funded projects to deliver. Successful projects should produce practical tools and approaches for risk-based quality assessment, contribute to science-based quality standards and regulatory policies, and/or create training tools that help industry and regulators competently apply the emerging technology. In other words, the work should not only generate data but also translate that data into decision-making frameworks, measurable standards, and guidance-ready practices that can be broadly adopted. The announcement also makes clear that results should be useful across stakeholders, meaning the knowledge should be accessible and relevant to both manufacturers and regulatory reviewers.
In terms of research focus, FDA highlights projects that improve the characterization and control of complex drug substances and complex dosage forms, including botanical drug substances. The grant points to three illustrative topic areas: (1) developing or validating appropriate analytical methods for complex substances or products, (2) designing and demonstrating effective in-process controls during manufacturing to ensure product quality, and (3) strengthening raw material quality control. These areas reflect recurring regulatory questions in pharmaceutical quality: how to measure what matters (analytics), how to control quality in real time or during processing (process controls), and how to prevent variability and contamination from entering upstream (materials control). Proposals are expected to clearly explain how the proposed technology or approach will move the field toward broad industrial readiness, improve control strategies, and/or make regulatory evaluation more robust for complex substances and dosage forms.
Mechanistically, this is a U01 cooperative agreement, which typically implies substantial programmatic involvement from the funding agency compared with a standard research grant. The opportunity is listed as "Clinical Trials Optional," indicating clinical trials are not required but are not automatically disallowed if they are relevant to the project aims. The administering agency is the US Department of Health and Human Services, Food and Drug Administration, and it falls under CFDA 93.103. The program anticipated a small number of awards (expected awards: 2) with an award ceiling of up to $5,000,000, signaling that FDA is aiming for a limited number of larger, high-impact projects rather than many small exploratory studies.
Eligibility is broad and includes public and private institutions of higher education, nonprofit organizations (with or without 501(c)(3) status), for-profit organizations (including small businesses), and various government entities and tribal organizations. The announcement lists multiple receipt dates across years (with deadlines in 2020, 2021, and 2022 as posted), reflecting a multi-deadline structure. Overall, the opportunity targets teams that can bridge rigorous pharmaceutical science with practical implementation and regulatory relevance, producing outputs that make advanced manufacturing and complex product assessment more predictable, standardized, and scalable across the drug lifecycle.Apply for PAR 20 083
- The Department of Health and Human Services, Food and Drug Administration in the agriculture, consumer protection, food and nutrition sector is offering a public funding opportunity titled "Enhancing Regulatory Science for Advancing Pharmaceutical Quality and Manufacturing (U01) Clinical Trials Optional" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.103.
- This funding opportunity was created on Jan 08, 2020.
- Applicants must submit their applications by Apr 10, 2020 Apr 02, 2022 This announcement has multiple deadlines Current Close Date April 10, 2020, by 1159 PM Eastern Time. April 3, 2021, by 1159 PM Eastern Time. April 2, 2022, by 1159 PM Eastern Time.. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Each selected applicant is eligible to receive up to $5,000,000.00 in funding.
- The number of recipients for this funding is limited to 2 candidate(s).
- Eligible applicants include: County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For profit organizations other than small businesses, Small businesses, Others (see text field entitled Additional Information on Eligibility for clarification).
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Browse more opportunities from the same agency: Department of Health and Human Services, Food and Drug Administration
Browse more opportunities from the same category: Agriculture, Consumer Protection, Food and Nutrition
Next opportunity: FY2020 National Environmental Information Exchange Network Grant Program
Previous opportunity: Bioequivalence of Topical Products: Elucidating Fundamental Principles of Dermal Pharmacokinetics for Microdialysis or Microperfusion Techniques (U01) Clinical Trials Not Allowed
Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PAR 20 083
Applicants also applied for:
Applicants who have applied for this opportunity (PAR 20 083) also looked into and applied for these:
| Funding Opportunity |
|---|
| Renewal - Investigation of impact of manufacturing difference and formulation variation on drug release for Levonorgestrel Intrauterine System (U01) Clinical Trials Not Allowed Apply for RFA FD 20 020 Funding Number: RFA FD 20 020 Agency: Department of Health and Human Services, Food and Drug Administration Category: Agriculture, Consumer Protection, Food and Nutrition Funding Amount: $600,000 |
| Novel Approaches to Advance Coordinated Registry Networks (CRNs) (U01 Clinical Trial Optional) Apply for RFA FD 20 021 Funding Number: RFA FD 20 021 Agency: Department of Health and Human Services, Food and Drug Administration Category: Agriculture, Consumer Protection, Food and Nutrition Funding Amount: $3,000,000 |
| Drug Development Tools Research Grants (U01 Clinical Trial Optional) Apply for RFA FD 20 009 Funding Number: RFA FD 20 009 Agency: Department of Health and Human Services, Food and Drug Administration Category: Agriculture, Consumer Protection, Food and Nutrition Funding Amount: $250,000 |
| Building an Integrated Laboratory System to Advance the Safety of Human and Animal Food (U18) Clinical Trial Not Allowed Apply for RFA FD 20 013 Funding Number: RFA FD 20 013 Agency: Department of Health and Human Services, Food and Drug Administration Category: Agriculture, Consumer Protection, Food and Nutrition Funding Amount: $500,000 |
| Conduct Studies to Establish More Targeted Durations of Use for Certain Approved Antimicrobial New Animal Drugs in Food Animals (U01) Clinical Trials Optional Apply for RFA FD 20 025 Funding Number: RFA FD 20 025 Agency: Department of Health and Human Services, Food and Drug Administration Category: Agriculture, Consumer Protection, Food and Nutrition Funding Amount: $500,000 |
| Advancing Conformance with the Voluntary National Retail Food Regulatory Program Standards (VNRFRPS) (U18) Clinical Trials Not Allowed Apply for RFA FD 20 012 Funding Number: RFA FD 20 012 Agency: Department of Health and Human Services, Food and Drug Administration Category: Agriculture, Consumer Protection, Food and Nutrition Funding Amount: $70,000 |
| Cooperative Agreement for Data Collection on Antimicrobial Use in Dogs and Cats (UO1) Clinical Trials Not Allowed Apply for RFA FD 20 026 Funding Number: RFA FD 20 026 Agency: Department of Health and Human Services, Food and Drug Administration Category: Agriculture, Consumer Protection, Food and Nutrition Funding Amount: $200,000 |
| Laboratory Flexible Funding Model (LFFM) (U19) Clinical Trials Not Allowed Apply for PAR 20 105 Funding Number: PAR 20 105 Agency: Department of Health and Human Services, Food and Drug Administration Category: Agriculture, Consumer Protection, Food and Nutrition Funding Amount: $1,500,000 |
| Integrated Pathogen Reduction Technologies for whole blood and blood components for transfusion (R01) Clinical Trial Not Allowed Apply for RFA FD 20 027 Funding Number: RFA FD 20 027 Agency: Department of Health and Human Services, Food and Drug Administration Category: Agriculture, Consumer Protection, Food and Nutrition Funding Amount: $8,000,000 |
| FDA's National Curriculum Standard Development and Training Delivery and Development (U18) Clinical Trial Not Allowed Apply for RFA FD 20 024 Funding Number: RFA FD 20 024 Agency: Department of Health and Human Services, Food and Drug Administration Category: Agriculture, Consumer Protection, Food and Nutrition Funding Amount: $1,500,000 |
| NARMS Cooperative Agreement Program to Strengthen Antibiotic Resistance Surveillance in Retail Food Specimens (U01) Clinical Trials Not Allowed Apply for PAR 20 124 Funding Number: PAR 20 124 Agency: Department of Health and Human Services, Food and Drug Administration Category: Agriculture, Consumer Protection, Food and Nutrition Funding Amount: $200,000 |
| Exploring the use of Real-World Data to Generate Real-World Evidence in Regulatory Decision-Making (U01) Clinical Trials Optional Apply for RFA FD 20 031 Funding Number: RFA FD 20 031 Agency: Department of Health and Human Services, Food and Drug Administration Category: Agriculture, Consumer Protection, Food and Nutrition Funding Amount: $12,000,000 |
| Development and Maintenance of the Animal Feed Regulatory Program Standards with Optional Coordinated Preventive Control Regulatory Activities and Capacity Building (U18) Clinical Trial Not Allowed Apply for PAR 20 132 Funding Number: PAR 20 132 Agency: Department of Health and Human Services, Food and Drug Administration Category: Agriculture, Consumer Protection, Food and Nutrition Funding Amount: $600,000 |
| Exploring the use of Real-World Data to Generate Real-World Evidence in Regulatory Decision-Making (U01) Clinical Trials Optional Apply for RFA FD 20 030 Funding Number: RFA FD 20 030 Agency: Department of Health and Human Services, Food and Drug Administration Category: Agriculture, Consumer Protection, Food and Nutrition Funding Amount: $12,000,000 |
| Retail Food Safety Association Collaboration (U18) Clinical Trial Not Allowed Apply for RFA FD 20 028 Funding Number: RFA FD 20 028 Agency: Department of Health and Human Services, Food and Drug Administration Category: Agriculture, Consumer Protection, Food and Nutrition Funding Amount: $1,500,000 |
| Cooperative Agreement to Support FDA Land and Water Initiative (U01) Clinical Trial Not Allowed Apply for RFA FD 20 034 Funding Number: RFA FD 20 034 Agency: Department of Health and Human Services, Food and Drug Administration Category: Agriculture, Consumer Protection, Food and Nutrition Funding Amount: $250,000 |
| Cooperative Agreement to Support an Evidence-based Clinical Practice Guideline for the Treatment of Acute Dental Pain (U01) Clinical Trials Not Allowed Apply for RFA FD 20 029 Funding Number: RFA FD 20 029 Agency: Department of Health and Human Services, Food and Drug Administration Category: Agriculture, Consumer Protection, Food and Nutrition Funding Amount: $1,500,000 |
| Drug Development Science Support (U01) Clinical Trials Optional Apply for RFA FD 20 033 Funding Number: RFA FD 20 033 Agency: Department of Health and Human Services, Food and Drug Administration Category: Agriculture, Consumer Protection, Food and Nutrition Funding Amount: $5,000,000 |
| CBER FY20 FOA for AAV vector manufacturing for diseases affecting very small populations (R01) Clinical Trial Not Allowed Apply for RFA FD 20 032 Funding Number: RFA FD 20 032 Agency: Department of Health and Human Services, Food and Drug Administration Category: Agriculture, Consumer Protection, Food and Nutrition Funding Amount: $800,000 |
| Renewal - Federal and University Partnership to Improve the Safety of Seafood from the Gulf of Mexico (U19) Clinical Trials Not Allowed Apply for RFA FD 21 009 Funding Number: RFA FD 21 009 Agency: Department of Health and Human Services, Food and Drug Administration Category: Agriculture, Consumer Protection, Food and Nutrition Funding Amount: $125,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Inside Our Applicants Portal
Access Applicants Portal
- Grants Repository - Access current and historic funding opportunities with ease. Thousands of funding opportunities are published every week. We can help you sort through the database and find the eligible ones to apply for.
- Applicant Video Guides - The grant application process can be challenging to follow. We can help you with intuitive video guides to speed up the process and eliminate errors in submissions.
- Grant Proposal Wizard - We have developed a network of private funding organizations and investors across the United States. We can reach out and submit your proposal to these contacts to maximize your chances of getting the funding you need.
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Learn More
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PAR 20 083", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.